Schrodinger Q2 revenue beats estimates, swings to profit

Schrodinger

05/08/2026 21:27

Overview
US molecular discovery platform's Q2 revenue grew 8%, beating analyst expectations
Net income for Q2 swung to profit from loss last year
Drug discovery revenue rose, aided by $10 mln milestone from Ajax Therapeutics acquisition

Outlook
Schrodinger sees 2026 ACV at $218 mln to $228 mln, up 10-15% over 2025
Company raises 2026 drug discovery revenue outlook to $65 mln-$75 mln after Ajax milestone
Operating expenses for 2026 expected to be less than 2025

Result Drivers
ACV GROWTH - Co said 27% increase in annual contract value reflected growing industry adoption of its predict-first approach to molecular discovery
SOFTWARE REVENUE DECLINE - Co attributed 10% drop in software revenue to continued progress in accelerated transition to hosted software licensing
DRUG DISCOVERY MILESTONE - Drug discovery revenue rose mainly due to $10 mln collaboration milestone from Ajax Therapeutics acquisition

Company press release: ID:nBw7F05Zna

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$58.89 mln
$47.23 mln (6 Analysts)
Q2 Net Income
 
$5.98 mln
 
Q2 Gross Profit
 
$32.43 mln
 
Q2 Operating Expenses
 
$73.98 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the software peer group is "buy"
Wall Street's median 12-month price target for Schrodinger Inc is $20.00, about 27.8% above its August 4 closing price of $15.65

Reuters Recommended Reads
Aug 5 - Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Aug 4 - Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Aug 3 - GeneDx Q2 revenue beats analyst estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)